花旗发表报告指，与云顶新耀-B(01952.HK)举行了最新会议，管理层指导2025年销售额为14亿人民币，包括Nefecon的10亿人民币和Xerava的4亿人民币。而Nefecon ...

Nefecon is designed to deliver budesonide, a potent immunosuppressant, to the Peyer’s patches to prevent the formation of pathogenic IgA1 and stop the disease at its source, setting the drug ...

【1 月 14 日，花旗发布报告称与云顶新耀举行最新会议】 花顶新耀管理层指导 2025 年销售额为 14 亿元，其中 Nefecon 为 10 亿元，Xerava 为 4 亿 ...

Nefecon is a formulation of the established immunology drug budesonide, which targets the Peyer’s patches that are over-active in patients with IgAN. The antibodies produced as a result lodge in ...

Calliditas Therapeutics is on course to launch its first product, Nefecon for rare disease primary IgA nephropathy (IgAN), in the first half of 2022 after getting the green light for an ...